Kanjinti

Amgen Inc🇺🇸 United States

FDA Page

Effective Date: Jun 23, 2026
Approval ID: 9a94f5b2-b84e-4987-8ea1-c4346db5a5fa
Products: 3 registered
Version: 23

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use KANJINTI safely and effectively. See full prescribing information for KANJINTI. KANJINTI (trastuzumab-anns) for injection, for intravenous use Initial U.S. Approval: 2019 KANJINTI (trastuzumab-anns) is biosimilar to HERCEPTIN (trastuzumab).

Quick Stats

Total Products3

Labelers2

Label Sections36

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.